Cargando…

Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans

TLR8 agonists have the potential for use as immunomodulatory components in therapeutic modalities for viral infections such as chronic HBV (CHB) and HIV. In this study, using peripheral blood samples from a phase 1a clinical trial, we examined the acute effects of a single oral administration of a s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayithan, Natarajan, Ghosh, Alip, Dwivedi, Ankit, Wallin, Jeffrey J., Tan, Susanna K., Chen, Diana, Kottilil, Shyam, Poonia, Bhawna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706304/ https://www.ncbi.nlm.nih.gov/pubmed/34960669 http://dx.doi.org/10.3390/v13122400

Ejemplares similares

Follicular Helper T (T(FH)) Cell Targeting by TLR8 Signaling For Improving HBsAg-Specific B Cell Response In Chronic Hepatitis B Patients
por: Ayithan, Natarajan, et al.
Publicado: (2021)

HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis
por: Poonia, Bhawna, et al.
Publicado: (2018)

IL-21–Deficient T Follicular Helper Cells Support B Cell Responses Through IL-27 in Patients With Chronic Hepatitis B
por: Khanam, Arshi, et al.
Publicado: (2021)

Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal
por: Ghosh, Alip, et al.
Publicado: (2020)

Therapeutic Potential of TLR8 Agonist GS‐9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators
por: Amin, Oliver E., et al.
Publicado: (2021)

Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients
por: Kim, Jin Hyang, et al.
Publicado: (2020)

Publisher Correction: Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients
por: Kim, Jin Hyang, et al.
Publicado: (2020)

CD38: an ecto-enzyme with functional diversity in T cells
por: Ghosh, Alip, et al.
Publicado: (2023)

Immune Correlates of COVID-19 Control
por: Poonia, Bhawna, et al.
Publicado: (2020)

2072. Of Mice and Men: HIV-induced CD38 expression on CD8+ T lymphocytes contributes to mitochondrial dysfunction and chronic inflammation despite antiretroviral therapy
por: Mathur, Poonam, et al.
Publicado: (2022)

Blockade of CCR4 breaks immune tolerance in chronic hepatitis B patients by modulating regulatory pathways
por: Khanam, Arshi, et al.
Publicado: (2023)

Peripheral PD-1(+) T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection
por: Romani, Sara, et al.
Publicado: (2019)

Tickling the TLR7 to cure viral hepatitis
por: Funk, Emily, et al.
Publicado: (2014)

Short‐duration treatment with the novel non‐nucleoside inhibitor CDI‐31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open‐label study
por: Chua, Joel V., et al.
Publicado: (2020)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)

Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2020)

A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection
por: Price, Angie S., et al.
Publicado: (2022)

Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8
por: Wang, Xiaoyu, et al.
Publicado: (2022)

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
por: Smirnov, DV, et al.
Publicado: (2013)

Correction to: Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2021)

TLR3 Agonist Poly-IC Induces IL-33 and Promotes Myelin Repair
por: Natarajan, Chandramohan, et al.
Publicado: (2016)

Levels of CD56+TIM-3- Effector CD8 T Cells Distinguish HIV Natural Virus Suppressors from Patients Receiving Antiretroviral Therapy
por: Poonia, Bhawna, et al.
Publicado: (2014)

Stimulation of Innate Immune Cells by Light-Activated TLR7/8 Agonists
por: Ryu, Keun Ah, et al.
Publicado: (2014)

Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
por: Alharbi, Arwaf S, et al.
Publicado: (2020)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis
por: Comstock, Emily, et al.
Publicado: (2017)

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
por: Dietsch, Gregory N., et al.
Publicado: (2016)

The Ultra-Potent and Selective TLR8 Agonist VTX-294 Activates Human Newborn and Adult Leukocytes
por: Dowling, David J., et al.
Publicado: (2013)

Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity
por: Beesu, Mallesh, et al.
Publicado: (2015)

Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy
por: Rodell, Christopher B., et al.
Publicado: (2019)

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation
por: Zhang, Bo-Dou, et al.
Publicado: (2022)

ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine
por: Kim, Sehui, et al.
Publicado: (2023)

Formulated Phospholipids as Non-Canonical TLR4 Agonists
por: Liang, Hong, et al.
Publicado: (2022)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

Pharmacological Activation of p53 during Human Monocyte to Macrophage Differentiation Attenuates Their Pro-Inflammatory Activation by TLR4, TLR7 and TLR8 Agonists
por: Namgaladze, Dmitry, et al.
Publicado: (2021)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
por: Michaelis, Katherine A., et al.
Publicado: (2019)

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
por: Turco, Verena, et al.
Publicado: (2023)

Comparison of human B cell activation by TLR7 and TLR9 agonists
por: Hanten, John A, et al.
Publicado: (2008)

Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists
por: Cheng, Kui, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8ac067d4nhdd5erp0894nplsfr